Nova Eye Medical Launches iTrack Advance
ASX Announcement General iTrack Molteno3 AlphaRET
8 Jun, 2022
2RT Pivotal Study and Regulatory Pathway Presentation
ASX Announcement General AlphaRET
3 May, 2022
Nova Eye Medical Announces Regulatory Pathway for AlphaRET 2RT in the USA
ASX Announcement General AlphaRET
3 May, 2022
EYE Appointment to AGS Board
ASX Announcement iTrack
31 Mar, 2022
Investor Presentation Half Year Results 31 December 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Global Revenue of A$6.5m for 6 Months Ended 31 Dec 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Half Yearly Report and Accounts
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Glaucoma Sales Update for 6 Months Ended 31 Dec 2021
ASX Announcement General iTrack
1 Feb, 2022
Presentation - Reducing Progression Rate of Age-Related Macular Degeneration
ASX Announcement General AlphaRET
21 Dec, 2021
Appendix 3Z Final Director's Interest Notice
ASX Announcement General
25 Nov, 2021
2021 Annual General Meeting Voting Results
ASX Announcement General
25 Nov, 2021
Presentation - Annual General Meeting 2021
ASX Announcement General
24 Nov, 2021
Withdrawal of AGM Resolutions 2,4,6,7,8 and 9 From Notice of Meeting
ASX Announcement General
24 Nov, 2021
Resignation of Mr Alex Sundich
ASX Announcement General
24 Nov, 2021
Jobkeeper Payments Notification
ASX Announcement General
11 Nov, 2021
US Government Stimulus Loan Forgiven
ASX Announcement General
26 Oct, 2021
Notice of Annual General Meeting
ASX Announcement General
21 Oct, 2021
5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021
ASX Announcement General iTrack Molteno3 AlphaRET
7 Oct, 2021
EYE FY21 Date of AGM & Closing Date for Director Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
30 Sep, 2021
Nova Eye Medical to Present at ASX Small to Mid-Cap Conference
ASX Announcement General iTrack Molteno3 AlphaRET
10 Sep, 2021
Nova Eye Medical Acquires Key Glaucoma Patents to Drive New Product Expansion
ASX Announcement General iTrack
26 Aug, 2021
Nova Eye Medical Reports 25% Growth in Glaucoma Device Sales for the 2021 Fiscal Year
ASX Announcement General
19 Aug, 2021
Appendix 4E
ASX Announcement General
19 Aug, 2021
Appendix 4G & Corporate Governance Statement
ASX Announcement General
19 Aug, 2021
Notice of Upcoming Investor Call – Full Year (FY21) Results
ASX Announcement General
11 Aug, 2021
Notice of change of interests of substantial holder
ASX Announcement General
29 Jul, 2021
Nova Eye Medical FY21 Trading Update
ASX Announcement General
20 Jul, 2021
Nova Eye Establishes Share Sale Facility for Unmarketable Parcels
ASX Announcement General
15 Jul, 2021
Nova Eye Medical Files IDE Application with the FDA to Commence a Pivotal Study in the US Evaluating 2RT
ASX Announcement AlphaRET
5 Jul, 2021
For investor enquires please contact:
Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More